A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of MK-6204 (SKB535) for Injection in Participants With Advanced Solid Tumors
A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of MK-6204 (SKB535) for Injection in Participants With Advanced Solid Tumors
Recruiting · NCT06726369 · Registry updated 2026-05-07Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of MK-6204 (SKB535) for Injection in Participants With Advanced Solid Tumors | Advanced Solid Tumors | Recruiting | Phase 1 | 2026-05-07 | NCT06726369 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 52 |
7 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Beijing Cancer hospital | Beijing | China | 84 |
| Chongqing University Cancer Hospital | Chongqing | China | 17 |
| Fujian Provincial Cancer Hospital | Fuzhou | China | 1 |
| Hubei Cancer Hospital | Wuhan | China | 23 |
| Hunan Cancer Hospital | Changsha | China | 2 |
| Shanghai East Hospital | Shanghai | China | 33 |
| West China Hospital of Sichuan University | Chengdu | China | 30 |